| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Revenue | 161,709 | 141,148 | 83,879 | 73,466 |
| Cost of revenue | 28,093 | 18,938 | 9,341 | 8,304 |
| Noncash compensation | 5,335 | 4,318 | 3,028 | 2,520 |
| Other research and development | 35,543 | 27,464 | 17,110 | 15,036 |
| Total research and development | 40,878 | 31,782 | 20,138 | 17,556 |
| Noncash compensation | 12,351 | 12,044 | 8,745 | 6,962 |
| Other selling, general and administrative | 51,022 | 43,541 | 33,221 | 31,828 |
| Total selling, general and administrative | 63,373 | 55,585 | 41,966 | 38,790 |
| Total costs and expenses | 132,344 | 106,305 | - | - |
| Operating income | 29,365 | 34,843 | 12,434 | 8,816 |
| Interest expense | 6,721 | 6,716 | 10,832 | 3,977 |
| Other income | 3,265 | 2,793 | 2,666 | 1,712 |
| Total other expense, net | -3,456 | -3,923 | -8,166 | -2,265 |
| Net income before taxes | 25,909 | 30,920 | 4,268 | 6,551 |
| Income tax benefit (expense) | -364,986 | 2,733 | 388 | -328 |
| Net income | 390,895 | 28,187 | 3,880 | 6,879 |
| Basic (in dollars per share) | 2.69 | 0.19 | 0.03 | 0.05 |
| Diluted (in dollars per share) | 2.43 | 0.17 | 0.02 | 0.04 |
| Us-gaap_weightedaveragenumberofdilutedsharesoutstanding | 160,997,977 | 162,559,404 | 160,714,388 | 159,423,571 |
| Weighted-average common shares outstanding (in shares) | 145,416,901 | 146,739,833 | 145,102,479 | 144,727,482 |
TG THERAPEUTICS, INC. (TGTX)
TG THERAPEUTICS, INC. (TGTX)